Ekso Bionics Holdings Inc
EKSO4.860USD
+0.040+0.83%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
12.75MMarket Cap
LossP/E TTM
More Details of Ekso Bionics Holdings Inc Company
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
Ekso Bionics Holdings Inc Info
Ticker SymbolEKSO
Company nameEkso Bionics Holdings Inc
IPO dateApr 10, 2013
CEODavis (Scott G)
Number of employees61
Security typeOrdinary Share
Fiscal year-endApr 10
Address101 Glacier Point
CitySAN RAFAEL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94901
Phone15109841761
Websitehttps://eksobionics.com/
Ticker SymbolEKSO
IPO dateApr 10, 2013
CEODavis (Scott G)
Company Executives of Ekso Bionics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Steven A. Sherman
Mr. Steven A. Sherman
Executive Chairman of the Board
Executive Chairman of the Board
449.16K
+23.08%
Ms. Mary Ann Cloyd
Ms. Mary Ann Cloyd
Independent Director
Independent Director
25.23K
+166.00%
Mr. Jason C. Jones
Mr. Jason C. Jones
Chief Operating Officer
Chief Operating Officer
19.91K
-1.34%
Mr. Jerome Wong
Mr. Jerome Wong
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
17.56K
-6.59%
Ms. Deborah Lafer Scher
Ms. Deborah Lafer Scher
Independent Director
Independent Director
15.75K
--
Dr. Charles Li, Ph.D.
Dr. Charles Li, Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott G. Davis
Mr. Scott G. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Corinna E. Lathan
Dr. Corinna E. Lathan
Independent Director
Independent Director
--
--
Mr. Stephen Kilmer
Mr. Stephen Kilmer
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Steven A. Sherman
Mr. Steven A. Sherman
Executive Chairman of the Board
Executive Chairman of the Board
449.16K
+23.08%
Ms. Mary Ann Cloyd
Ms. Mary Ann Cloyd
Independent Director
Independent Director
25.23K
+166.00%
Mr. Jason C. Jones
Mr. Jason C. Jones
Chief Operating Officer
Chief Operating Officer
19.91K
-1.34%
Mr. Jerome Wong
Mr. Jerome Wong
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
17.56K
-6.59%
Ms. Deborah Lafer Scher
Ms. Deborah Lafer Scher
Independent Director
Independent Director
15.75K
--
Dr. Charles Li, Ph.D.
Dr. Charles Li, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.02M
49.73%
Other EMEA
613.00K
29.80%
France
365.00K
17.74%
APAC
40.00K
1.94%
Other Americas
16.00K
0.78%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Davis (Scott Gerald)
2.33%
Consolidated Portfolio Review Corp
1.91%
Citadel Advisors LLC
1.14%
The Vanguard Group, Inc.
1.04%
UBS Financial Services, Inc.
0.96%
Other
92.62%
Shareholders
Shareholders
Proportion
Davis (Scott Gerald)
2.33%
Consolidated Portfolio Review Corp
1.91%
Citadel Advisors LLC
1.14%
The Vanguard Group, Inc.
1.04%
UBS Financial Services, Inc.
0.96%
Other
92.62%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.59%
Investment Advisor
4.73%
Hedge Fund
1.57%
Investment Advisor/Hedge Fund
1.05%
Research Firm
0.33%
Family Office
0.03%
Other
85.70%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
64
261.39K
8.72%
--
2025Q3
67
261.39K
11.41%
+205.54K
2025Q2
64
55.85K
14.40%
-195.55K
2025Q1
62
251.40K
15.39%
-37.98K
2024Q4
61
283.25K
26.99%
-87.09K
2024Q3
58
370.34K
18.68%
+159.85K
2024Q2
61
145.58K
14.28%
+25.92K
2024Q1
67
120.72K
11.67%
-18.52K
2023Q4
71
95.15K
14.09%
+2.45K
2023Q3
71
92.88K
16.51%
-13.62K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Davis (Scott Gerald)
22.27K
0.85%
+7.04K
+46.23%
Mar 18, 2025
The Vanguard Group, Inc.
11.96K
0.46%
-27.61K
-69.77%
Jun 30, 2025
Li (Kecheng)
30.73K
1.18%
+15.75K
+105.11%
May 16, 2025
Lathan (Corinna)
25.61K
0.98%
+15.75K
+159.61%
May 16, 2025
Cloyd (Mary Ann)
25.23K
0.97%
+15.75K
+166.00%
May 16, 2025
Jones (Jason C)
14.90K
0.57%
+5.26K
+54.55%
Mar 18, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 19, 2025
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Date
Type
Ratio
May 19, 2025
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
Mar 24, 2020
Merger
15→1
FAQs
Who are the top five shareholders of Ekso Bionics Holdings Inc?
The top five shareholders of Ekso Bionics Holdings Inc are:
Davis (Scott Gerald) holds 22.27K shares, accounting for 0.85% of the total shares.
The Vanguard Group, Inc. holds 11.96K shares, accounting for 0.46% of the total shares.
Li (Kecheng) holds 30.73K shares, accounting for 1.18% of the total shares.
Lathan (Corinna) holds 25.61K shares, accounting for 0.98% of the total shares.
Cloyd (Mary Ann) holds 25.23K shares, accounting for 0.97% of the total shares.
Davis (Scott Gerald) holds 22.27K shares, accounting for 0.85% of the total shares.
The Vanguard Group, Inc. holds 11.96K shares, accounting for 0.46% of the total shares.
Li (Kecheng) holds 30.73K shares, accounting for 1.18% of the total shares.
Lathan (Corinna) holds 25.61K shares, accounting for 0.98% of the total shares.
Cloyd (Mary Ann) holds 25.23K shares, accounting for 0.97% of the total shares.
What are the top three shareholder types of Ekso Bionics Holdings Inc?
The top three shareholder types of Ekso Bionics Holdings Inc are:
Davis (Scott Gerald)
Consolidated Portfolio Review Corp
Citadel Advisors LLC
Davis (Scott Gerald)
Consolidated Portfolio Review Corp
Citadel Advisors LLC
How many institutions hold shares of Ekso Bionics Holdings Inc (EKSO)?
As of 2025Q4, 64 institutions hold shares of Ekso Bionics Holdings Inc, with a combined market value of approximately 261.39K, accounting for 8.72% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.70%.
What is the biggest source of revenue for Ekso Bionics Holdings Inc?
In FY2025Q2, the -- business generated the highest revenue for Ekso Bionics Holdings Inc, amounting to -- and accounting for --% of total revenue.
